TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

tunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 207. 1.1209 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009; 58(RR-11):1-167. 2A.1 Zheng X et al. Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates. J Clin Microbiol 2004;42:4323-6. 2A.2 Gómez-Cerezo J et al. Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases. Eur J Clin Microbiol Infect Dis 2003;22:360-3. 2A.3 Yildiz O et al. Actinomycoses and Nocardia pulmonary infections. Curr Opin Pulm Med 2006;12: 228-34. 2A.4 Smith AJ et al. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother 2005;56:407-9. 2A.5 von Graevenitz A. The role of Aeromonas in diarrhea: a review. Infection 2007;35:59-64. 2A.6 Sader HS et al. Antimicrobial susceptibility of uncommonly isolated non enteric Gram negative bacilli. Int J Antimicrob Agents 2005;25:95-109. 2A.7 Streit JM et al. Prevalence and antimicrobial susceptibility patterns among gastro-enteritis causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY antimicrobial surveillance program (2003). Int J Antimicrob Agents 2006;27:378-86. 2A.8 Janda JM et al. The genus Aeromonas: taxonomy, pathogenicity and infection. Clin Microbiol Rev 2010;23:35-73. 2A.9 Lamy B et al. Prospective nationwide study of Aeromonas infections in France. J Clin Microbiol 2009; 47:1234-7. 2A.10 Nørskov-Lauritsen N et al. Reclassification of Actinobacillus actinomycetemcomitans, Haemophilus aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans, gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter segnis comb. nov., and emended description of Aggregatibacter aphrophilus to include V factor-dependent and V factor-independent isolates. Int J Syst Evol Microbiol 2006;56:2135-46. 2A.11 Nørskov-Lauritsen N et al. Reclassification of Actinobacillus actinomycetemcomitans, Haemophilus aphrophilus, Haemophilus paraphrophilus and Haemophilus segnis as Aggregatibacter actinomycetemcomitans, gen. nov., comb. nov., Aggregatibacter aphrophilus comb. nov. and Aggregatibacter segnis comb. nov., and emended description of Aggregatibacter aphrophilus to include V factor-dependent and V factor-independent isolates. Int J Syst Evol Microbiol 2006;56:2135-46. 2A.12 Baddour LM et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 2005;111:e394-433. 2A.13 Sader HS et al. Antimicrobial susceptibility of uncommonly isolated non enteric Gram negative bacilli. Int J Antimicrob Agents 2005;25:95-109. 2A.14 Dumler JS et al. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis 2007;45(suppl. 1):S45-51. 2A.15 Horowitz HW et al. Antimicrobial susceptibility of Ehrlichia phagocytophila. Antimicrob Agents Chemother 2001;45:786-8. 2A.16 Branger S et al. Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeen-sis and Anaplasma phagocytophilum by real time PCR. Antimicrob Agents Chemother 2004;48:4822-8. 2A.17 Carlson P et al. Antimicrobial susceptibility of Arcanobacterium haemolyticum. Antimicrob Agents Chemother 1994;38:142-3. 2A.18 Carlson P et al. Antimicrobial susceptibilities and biotypes of Arcanobacterium haemolyticum blood isolates. Eur J Clin Microbiol Infect Dis 1999;18:915-7. 2A.19 Athamna A et al. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time kill activity. J Antimicrob Chemother 2004;53:247-51. 2A.20 Jones ME et al. Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare. Clin Microbiol Infect 2003;9:984-6. 2A.21 Werlinger KD et al. Therapy of other bacterial infections. Dermatol Ther 2004;17:505-12. 2A.22 Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev 2010;23:382-98. 2A.23 Snydman DR et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010;50(suppl. 1):S26-33. 2A.24 Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev 2007;20:593- 621. 2A.25 Wybo I et al. Third Belgian multicentre survey of antibiotic susceptibility of anerobic bacteria. J Antimicrob Chemother 2007;59:132-9. 2A.26 Glupczynski Y et al. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by Etest methodology. Eur J Clin Microbiol Infect Dis 2009;28:261-7. 2A.27 Pendle S et al. Antimicrobial susceptibility of Bartonella henselae using E-test methodology. J Antimicrob Chemother 2006;57:761-3. 2A.28 Foucault C et al. Bartonella quintana characteristics and clinical management. Emerg Infect Dis 2006;12:216-23. 2A.29 Rolain JM et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004;48:1921-33. 2A.30 Moubareck C et al. Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother 2005;55: 38-44. 2A.31 Altunaiji S et al. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007;3: CD004404. 2A.32 Mattoo S et al. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326- 82. 2A.33 Cutler SJ et al. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol Infect 2009;15:400-6. 2A.34 Ružić-Sabljić E et al. Susceptiblility of Borrelia afzelii strains to antimicrobial agents. Int J Antimicrob Agents 2005;25:474-8. 2A.35 Hunfeld KP et al. In vitro susceptibility of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 2005;49:1294-301.
2A.36 Wormser GP. Early Lyme disease. N Engl J Med 2006;354:2794-801. 2A.37 Halperin JJ et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review). Report of the American Academy of Neurology Quality Standards Subcomittee. Neurology 2007;69:91-102. 2A.38 Skalsky K et al. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. Br Med J 2008;336:701-4. 2A.39 Baykam N et al. In vitro antimicrobial susceptibility of Brucella species. Int J Antimicrob Agents 2004;23:405-7. 2A.40 Franco MP et al. Human brucellosis. Lancet Infect Dis 2007;7:775-86. 2A.41 Avgeri SE et al. Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents 2009:33:394-404. 2A.42 Mahenthiralingam E et al. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol 2005;3:144-56. 2A.43 Wuthiekanun V et al. Management of melioidosis. Expert Rev Anti Infect Ther 2006;4:445-55. 2A.44 Thibault FM et al. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 2004;54:1134-8. 2A.45 Cheng AC et al. Melioidosis: epidemiology, pathophysiology and management. Clin Microbiol Rev 2005;18:383-416. 2A.46 Peacock SJ. Melioidosis. Curr Opin Infect Dis 2006;19:421-8. 2A.47 Chierakul W et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 2005;41:1105-13. 2A.48 Estes MD et al. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther 2010;8:325-38. 2A.49 Vandenberg O et al. Antimicrobial susceptibility of clinical isolates of non jejuni/coli Campylobacter and Arcobacter from Belgium. J Antimicrob Chemother 2006;57:908-13. 2A.50 Gibreel A et al. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother 2006;58:243-55. 2A.51 Blasi F et al. Chlamydophila pneumoniae. Clin Microbiol Infect 2009;15:29-35. 2A.52 Haggerty CL et al. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis 2007;44:953-60. 2A.53 Bauer MP et al. Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis 2009;22:517-24. 2A.54 Nelson R. Antibiotic treatment of Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007;3:CD004610. 2A.55 Johnson S et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8. 2A.56 Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007;45 (suppl. 2):S122-8. 2A.57 Brook I. Current concepts in the management of Clostridium tetani infection. Expert Rev Anti Infect Ther 2008;6:327-36. 2A.58 Kneen R et al. Penicillin versus erythromycin in the treatment of diphtheria. Clin Infect Dis 1998;27: 845-50. 2A.59 Parker NR et al. Q fever. Lancet 2006;367:679-88. 2A.60 Tissot-Dupont H et al. Q fever. Infect Dis Clin North Am 2008;22:505-14. 2A.61 Klaassen CH et al. Multigenotype Q fever outbreak, the Netherlands. Emerg Infect Dis 2009;15:613- 4. 2A.62 Stock I et al. Natural antibiotic susceptibilities of Edwardsiella tarda, Edwardsiella ictaluri and Edwardsiella hoshinae. Antimicrob Agents Chemother 2001;45:2245-55. 2A.63 Dumler JS et al. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis 2007;45(suppl. 1):S45-51. 2A.64 Branger S et al. Evaluation of antibiotic susceptibilities of Ehrlichia canis, Ehrlichia chaffeensis and Anaplasma phagocytophilum by real time PCR. Antimicrob Agents Chemother 2004;48:4822-8. 2A.65 Sheng WS et al. Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates. Eur J Clin Microbiol Infect Dis 2001;20:231-6. 2A.66 Kim KK et al. Transfer of Chryseobacterium meningosepticum and Chryseobacterium miricola to Elizabethkingia gen. nov. as Elizabethkingia meningoseptica comb. nov. and Elizabethkingia miricola comb. nov. Int J Syst Evol Microbiol 2005;55:1287-93. 2A.67 Kirby JT et al. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: report from the SENTRY antimicrobial surveillance program (1997-2001). J Clin Microbiol 2004;42:445-8. 2A.68 Di Pentima MC et al. In vitro antibiotic synergy against Flavobacterium meningosepticum: implications for therapeutic options. Clin Infect Dis 1998;26:1169-76. 2A.69 Fidalgo SG et al. Susceptibility of Erysipelothrix rhusiopathiae to antimicrobial agents and home disinfectants. Pathology 2002;34:462-5. 2A.70 Kaper JB et al. Pathogenic Eschericha coli. Nat Rev Microbiol 2004;2:123-40. 2A.71 De Backer D et al. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 10 year interval. J Antimicrob Chemother 2008;62:364-8. 2A.72 Ikäheimo I et al. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother 2000;46:287-90. 2A.73 Tärnvik A et al. New approaches to diagnosis and therapy of tularaemia. Ann NY Acad Sci 2007; 1105:378-404. 2A.74 Nigrovic LE et al. Tularemia. Infect Dis Clin North Am 2008;22:489-504. 2A.75 Nyfors S et al. Emergence of penicillin resistance among Fusobacterium nucleatum populations of commensal oral flora during early childhood. J Antimicrob Chemother 2003;51:107-12. 2A.76 Glupczynski Y et al. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by Etest methodology. Eur J Clin Microbiol Infect Dis 2009;28:261-7. 2A.77 Collins MD et al. The genus Abiotrophia (Kawamura et al.) is not monophyletic: proposal of Granulicatella gen. nov., Granulicatella adiacens comb. nov., Granulicatella elegans comb. nov. and Granulicatella balaenopterae comb. nov. Int J Syst Evol Microbiol 2000;50:365-9. 2A.78 Roy-Leon JE et al. In vitro and in vivo activity of combination antimicrobial agents on Haemophilus ducreyi. J Antimicrob Chemother 2005;56:552-8.
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27: 1.1166 Aldape MJ et al. Clostridium
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80:
duct characteristics. Available at:
Page 81 and 82:
_Product_Information/human/000338/W
Page 83 and 84:
114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86:
North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88:
1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90:
21.358 Calabrese LH et al. Viral Ar
Page 91 and 92:
24. 21.452 Jeha LE et al. Long term
Page 93 and 94:
induced functional androgen deficie
Page 95 and 96:
25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?